IP Library Granted Patent US 9,820,975
Granted Patent B2
US 9,820,975 · App. 15/133,534 · Granted Nov 21, 2017

Compounds and methods for treating influenza

Inventors: Jean-Francois Rossignol (St. Petersburg, FL); J. Edward Semple (Tampa, FL)
Assignee: Romark Laboratories L.C.
A61K31/426A61K9/0053A61K9/2086A61K31/215A61K31/351A61K31/454A61K31/496A61K31/675A61K31/7105A61K45/06H01L31/125A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,820,975
App. No.
15/133,534
Granted
Nov 21, 2017
Kind
B2
Abstract

This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.

Claims (13)

1. A method of treating a viral infection which is caused by a virus selected from Parainfluenza virus, Coronavirus, Adenovirus and Respiratory syncytial virus comprising:

administering to a subject in need thereof an affective amount of nitazoxanide or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the viral infection is caused by the Parainfluenza virus.

3. The method of claim 1 , wherein the viral infection is caused by the Coronavirus.

4. The method of claim 1 , wherein the viral infection is caused by the Adenovirus.

5. The method of claim 1 , wherein the viral infection is caused by the Respiratory syncytial virus.

6. The method of claim 1 , wherein the subject has influenza-like symptoms.

7. The method of claim 1 , wherein said administering is performed orally.

8. The method of claim 7 , wherein said administering comprises administering the nitazoxanide or a pharmaceutically acceptable salt thereof at a dose of 300 mg or 600 mg twice daily.

9. The method of claim 8 , wherein said administering is performed for 5 days.

10. The method of claim 1 , wherein the nitazoxanide or a pharmaceutically acceptable salt thereof is administered as modified release bi-layer tablet.

11. The method of claim 10 , wherein the nitazoxanide or a pharmaceutically acceptable salt thereof is administered in 100 mg, 200 mg, 300 mg, 400 mg, 500 mg or 600 mg doses twice daily.

12. The method of claim 11 , wherein said administering is performed for 5 days.

Assignments (3)
SECURITY INTEREST Recorded Nov 16, 2019
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051030/0613 →
SECURITY INTEREST Recorded Jul 2, 2018
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 046254/0524 →
SECURITY INTEREST Recorded Dec 22, 2017
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 044472/0001 →
Continuity (4)
Continuation 14658409 · Mar 16, 2015
Continuation 12821571 · Jun 23, 2010
Provisional Application 61220891 · Jun 26, 2009
Related Publication 20160228415A1 · Aug 11, 2016